Hanall Biopharma Discloses Corporate Governance Report: No Dividends for 3 Consecutive Years, Continued Operating Loss, Long-Term Dividend Policy Established but Shareholder Returns Remain Uncertain
Hanall Biopharma disclosed its corporate governance report. For the fiscal year 2025, consolidated revenue reached 155.18 billion KRW (+11.7% YoY), but operating loss was 9.1 billion KRW and net loss was 55.6 billion KRW, indicating continued profitability deterioration.
The company has not paid any cash or stock dividends for the past three years. In October 2025, it established and disclosed a mid-to-long term dividend policy, but the specific timing and amount of implementation remain uncertain.
The board consists of 3 inside directors, 2 outside directors, and 1 other non-executive director, with outside directors comprising 33% meeting legal requirements. However, all members are male, lacking gender diversity, and the board chairman is an inside director.
No share buyback or cancellation was conducted, and no material events such as designation as an unfaithful disclosure entity or change in management control occurred during the period.
[AI Summary]Hanall Biopharma's corporate governance report meets legal disclosure requirements without additional positive or negative surprises, but sustained operating losses and absence of dividends weigh on short-term shareholder value. The focus remains on whether R&D-driven growth strategy will create long-term value.